title: Gender-specific effects in the treatment of acute schizophrenia with risperidone.
abstract: BACKGROUND
  Gender-related effects play a role in antipsychotic treatment. We recently published a study demonstrating the efficacy of the atypical antipsychotic risperidone in the management of acute psychotic decompensations. We have now reanalysed the clinical data to assess the effects of gender on treatment and outcome.
  
  
  METHODS
  High-dose treatment with risperidone (6-8 mg/d) was administered to 23 male and 25 female acutely psychotic schizophrenic admissions. PANSS- and CGI-ratings were obtained for four weeks.
  
  
  RESULTS
  Males and females did not differ significantly in age, duration of treatment, dose of risperidone or clinical ratings. Females were treated with a significantly higher maximum dose of risperidone per kg body-weight. Significantly more females (n=14) than males (n=8) discontinued the use of risperidone.
  
  
  CONCLUSIONS
  Although the reasons for the lower drop-out rate in males are not clear, gender differences in the clinical presentation may have contributed. High-dose treatment with risperidone may be more beneficial in males for the treatment of acute schizophrenia.
authors.affiliation: Department of Psychiatry, University Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. traedler@uke.uni-hamburg.de
authors.forename: T J
authors.initials: TJ
authors.lastname: Raedler
authors.forename: A
authors.initials: A
authors.lastname: Schreiner
authors.forename: D
authors.initials: D
authors.lastname: Naber
authors.forename: K
authors.initials: K
authors.lastname: Wiedemann
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D011569:Psychiatric Status Rating Scales; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012727:Sex Characteristics; D012737:Sex Factors; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone